INKT
MiNK Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.56
+1.59%Sep 30, 2026, 11:57 UTC
MiNK Therapeutics was selected to provide its agenT-797 iNKT cell therapy platform for the ARPA-H-funded BoSS program, which aims to move living medicines from cryogenic storage toward room temperature.
Source:Aug 13, 2026, 11:30 UTC
MiNK Therapeutics reported its financial results for the second quarter ended June 30, 2026.